Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Pooled data from 5 double-blind, placebo-controlled Phase I trials in 94 healthy volunteers showed that single doses of 0.2-2,000 mg IV
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury